Avorn, J. (1984), ‘Benefit and cost analysis in geriatric care – turning age discrimination into health policy’, New England Journal of Medicine, 310: 129–130.
Baker, R., Bateman, I., Donaldson, C., Jones-Lee, M., Lancsar, E., Loomes, G., Mason, H., Odejar, M., Pinto-Prades, J.L., Robinson, A., Ryan, M., Shackley, P., Smith, R., Sugden, R., Wildman, J. (2010), ‘Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the social value of a QALY project’, Health Technology Assessment, 14(27): 1–162.
Cookson, R., Tsuchiya, A.McCabe, C. (2008), ‘Public resource allocation and the rule of rescue’, Journal of Medical Ethics, 34: 540–544.
Culyer, A. J. (1995), ‘Need: the idea won't do – but we still need it’, Social Science & Medicine, 40(6): 727–730.
Culyer, A. J. (2005), ‘Involving stakeholders in healthcare decisions – the experience of the National Institute for Health and Clinical Excellence (NICE) in England and Wales’, Healthcare Quarterly, 8: 56–60.
Culyer, A. J.Lomas, J. (2006), ‘Deliberative processes and evidence-informed decision-making in health care – do they work and how might we know?’, Evidence and Policy, 2: 357–371.
Daniels, N. (2000), ‘Accountability for reasonableness’, British Medical Journal, 321: 1300–1301.
Daniels, N.Sabin, J. E. (2008), ‘Accountability for reasonableness: an update’, British Medical Journal, 337: a1850.
Department of Health (2010), A New Value-Based Approach to the Pricing of Branded Medicines – a Consultation, London: Department of Health.
Dolan, P., Edlin, R., Tsuchiya, A., Armitage, C., Hukin, A., Brazier, J., Ibbotson, R., Bryan, S., Eiser, D., Olsen, J.A. (2008), The Relative Societal Value of Health Gains to Different Beneficiaries: Final Report to NICE, London: National Institute for Health and Clinical Excellence.
Grimley-Evans, J. (1992), ‘Quality of Life Assessments and Elderly People’, in A. Hopkins (ed.), Measures of the Quality of Life and the Uses to Which such Measures may be put, London: Royal College of Physicians.
Harris, J. (2005), ‘It's not NICE to discriminate’, Journal of Medical Ethics, 31: 373–375.
Hoover, D. R., Crystal, S., Kumar, R., Sambamoorthi, U.Cantor, J. C. (2002), ‘Medical expenditures during the last year of life: findings from the 1992–1996 medicare current beneficiary survey’, Health Services Research, 37: 1625–1642.
Jonsen, A. R.Toulmin, S. (1988), The Abuse of Casuistry: A History of Moral Reasoning, Berkeley: University of California Press.
Kennedy, I. (2009), Appraising the value of innovation and other benefits: a short study for NICE, London: NICE.
Littlejohns, P.Rawlins, M. (eds) (2009), Patients, the public and priorities in healthcare, Oxon: Radcliffe Publishing.
Longson, C.Littlejohns, P. (2009), Update Report on the Application of the ‘End-of-Life’ Supplementary Advice in Health Technology Appraisals, London: NICE.
McKie, J.Richardson, J. (2003), ‘The rule of rescue’, Social Science & Medicine, 56(12): 2407–2419.
National Institute for Health and Clinical Excellence (NICE) (2001), Guidance on the use of Riluzole (Rilutek) for the Treatment of Motor Neurone Disease, London: NICE.
NICE (2002), Guidance on the use of Trastuzumab for the Treatment of Advanced Breast Cancer, London: NICE.
NICE (2003), Guide to the Methods of Technology Appraisal, London: NICE.
NICE (2006a), Final Appraisal Determination: Pemetrexed Disodium for the Treatment of Malignant Pleural Mesothelioma, London: NICE.
NICE (2006b), Appraisal of Pemetrexed Disodium for the Treatment of Malignant Pleural Mesothelioma: Decision of the Panel, London: NICE.
NICE (2007), Omalizumab for Severe Persistent Allergic Asthma, London: NICE.
NICE (2008a), Social Value Judgements: Principles for the Development of NICE Guidance, 2nd edition, London: NICE.
NICE (2008b), Guide to the Methods of Technology Appraisal (second edition), London: NICE.
NICE (2008c), Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women, London: NICE.
NICE (2008d), Pemetrexed for the Treatment of Malignant Pleural Mesothelioma, London: NICE.
NICE (2008e), Appraisal of Pemetrexed for the Treatment of Malignant Pleural Mesothelioma: Decision of the Panel, London: NICE.
NICE (2008f), Smoking Cessation Services in Primary Care, Pharmacies, Local Authorities and Workplaces, Particularly for Manual Working Groups, Pregnant Women and Hard to Reach Communities, London: NICE.
NICE (2009a), Methods for the Development of NICE Public Health Guidance (second edition), London: NICE.
NICE (2009c), Bevacizumab (first-line), Sorafenib (first- and second-line), Sunitinib (second-line) and Temsirolimus (first-line) for the Treatment of Advanced and/or Metastatic renal Cell Carcinoma, London: NICE.
NICE (2010), Human Growth Hormone (Somatropin) for the Treatment of Growth Failure in Children, London: NICE.
Paulden, M., Culyer, A. J. (2010), ‘Does Cost-effectiveness Analysis Discriminate Against Patients with Short Life Expectancy? Matters of Logic and Matters of Context’. CHE Research Paper 55. York: Centre for Health Economics, University of York.
Rawlins, M. (2004), Scientific and Social Value Judgements, London: NICE.
Rawlins, M., Barnett, D.Stevens, A. (2010), ‘Pharmacoeconomics: NICE's approach to decision-making’, British Journal of Clinical Pharmacology, 70(3): 346–349.
Rawlins, M. D.Culyer, A. J. (2004), ‘National institute for clinical excellence and its value judgements’, British Medical Journal, 329: 224–227.
Shah, K. K. (2009), ‘Severity of illness and priority setting in healthcare: a review of the literature’, Health Policy, 93: 77–84.
Stevens, A., Doyle, N., Littlejohns, P., Docherty, M. (2012), ‘National institute for health and clinical excellence appraisal and ageism’, Journal of Medical Ethics, doi: 10.1136/medethics-2011-100129.
